FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
KCBS Radio San Francisco on MSN2d
As Prescribed: The evolving landscape of chronic pain treatment
Chronic pain affects approximately 1 in 5 Americans, and yet it remains one of the most misunderstood and challenging medical ...
Reviewers Say This Foot Massager Relieves Plantar Fasciitis Pain Like No Other — And It’s Only $42
After a long day — you want to take a load off. Yet, instead of kicking your feet up, try laying them on this highly-rated ...
What Really Works for Nerve Pain
Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...
btimesonline1d
FDA Greenlights Groundbreaking Pain Medication, But Is It Effective Enough?
The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...
clinicalpainadvisor.com12h
Chronic Pain Among Women in Rheumatology — Prioritizing Unmet Needs
Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.